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Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder,
starting in early childhood and persisting into adulthood in the majority of cases. Family and
twin studies have demonstrated the importance of genetic factors and candidate gene
association studies have identified several loci that exert small but significant effects on ADHD.
To provide further clarification of reported associations and identify novel associated genes, we
examined 1038 single-nucleotide polymorphisms (SNPs) spanning 51 candidate genes involved
in the regulation of neurotransmitter pathways, particularly dopamine, norepinephrine and
serotonin pathways, in addition to circadian rhythm genes. Analysis used within family tests of
association in a sample of 776 DSM-IV ADHD combined type cases ascertained for the
International Multi-centre ADHD Gene project. We found nominal significance with one or more
SNPs in 18 genes, including the two most replicated findings in the literature: DRD4 and DAT1.
Gene-wide tests, adjusted for the number of SNPs analysed in each gene, identified associations
with TPH2, ARRB2, SYP, DAT1, ADRB2, HES1, MAOA and PNMT. Further studies will be needed
to confirm or refute the observed associations and their generalisability to other samples.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a
common and highly heritable neurodevelopmental
disorder1 that affects 3–10% of children and 2–4% of
adults,2,3 depending on the measure used and the
population sampled. The disorder is characterised by
childhood onset of age-inappropriate and impairing
hyperactivity, impulsivity and inattentiveness. ADHD
is frequently accompanied by developmental pro-
blems, including dyslexia and specific and general
learning difficulties and high levels of comorbidity
with antisocial, mood, anxiety and substance use
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disorders. ADHD children are at high risk of nega-
tive long-term outcomes including academic under-
achievement, unemployment, high accident rates and
difficulty sustaining stable relationships.4 Recogni-
tion and appropriate treatment of ADHD across the
lifespan is therefore of considerable importance.5,6
The familial risk for ADHD is established with an
estimated sibling risk ratio (ls = risk to siblings of
ADHD probands/population risk) for broadly defined
ADHD of around three- to four-fold. ls values for
DSM-IV combined subtype are estimated to be
slightly higher, between five- to six-fold.7 The
analysis from Todd et al.7 suggests that DSM-IV
combined type ADHD may be a genetically homo-
geneous subgroup, since this subtype fell within a
single empirically derived latent class that showed
high levels of subtype concordance in their data set of
monozygotic and dizygotic twins. A review of 20 twin
studies found the heritability of ADHD to be 76%.8
Group heritabilities, derived from De Fries and Fulker
(DF) regression analysis with various thresholds on
ADHD symptom scales, suggests that genetic influ-
ences on ADHD are continuously distributed through-
out the population. Both individual differences and
DF approaches to bivariate twin analysis find a high
level of shared genetic effects between ADHD
and various comorbid disorders/traits including
dyslexia,9,10 conduct disorders and general cognitive
ability.11
To date, there have been four published genome
linkage scans of ADHD; three affected sibling pair
studies and one of 16 multiplex pedigrees.12–18 These
studies have highlighted a number of potential
linkage regions for further exploration, although there
is as yet no clear consensus across the various data
sets and no genes have been identified that account
for linkage signals. Several of the linkage regions
overlap in two or more of these studies, including
regions of chromosomes 5p, 6q, 7p, 11q, 12q and 17p,
suggesting that one or more loci of moderately large
effect may exist.
Meta-analyses of candidate gene studies have
successfully identified several genes of small effect
associated with ADHD. The genes identified so far are
involved in the regulation of catecholamine and other
neurotransmitter pathways and follow on from a
priori hypotheses of the role of dopamine pathways in
particular. Both children and adults with ADHD show
a rapid therapeutic response to methylphenidate and
amphetamine, which is mediated by blockade of
dopamine re-uptake with a subsequent increase in
synaptic dopamine.
A role for the serotonin system is suggested since it
is known to interact with dopamine in the control
of impulsive behaviour,19 and mediates stimulant
response of hyperactivity in dopamine transporter
knockout mice.20 The therapeutic effects of
atomoxetine, a specific noradrenergic reuptake in-
hibitor, directly implicate norepinephrine. Candidate
genes suggested by these observations include genes
that code for catecholamine neurotransmitter recep-
tors, enzymes involved in the metabolism and
degradation of the neurotransmitters and genes that
regulate the vesicular release of neurotransmitters
(synaptosomal proteins),21 and influence neuronal
membrane fluidity and responsiveness (fatty acid
desaturases).22
Meta-analysis of genetic variants reported to be
associated with ADHD in three or more studies found
average odds ratios (OR) across studies to be in the
order of 1.2–1.4. The genetic variants listed in this
study include the 7-repeat allele of an exon 3 variable
number tandem repeat (VNTR) in the dopamine D4
receptor gene (DRD4), a common allele of a micro-
satellite marker in the vicinity of the dopamine D5
receptor gene (DRD5), the 10-repeat allele of a VNTR
marker in the 30UTR region of the dopamine trans-
porter gene (DAT1), the long repeat of a VNTR in the
promotor region of the serotonin transporter gene
(HTTLPR) and single-nucleotide polymorphisms
(SNPs) located in the synaptosomal associated pro-
tein (SNAP-25) and the serotonin 5HT1B receptor
gene (HTR1B). Assuming a simple additive model the
combined effect size across the associated genetic
variants is estimated to contribute around 3–4% to
phenotypic variance leaving a substantial portion of
the additive genetic influences on ADHD to be
explained (Kuntsi et al., under review).
Another group of candidate genes that have yet to
be investigated are the circadian rhythm genes. The
rationale for their inclusion in genetic studies of
ADHD is that insomnia occurs in up to 54% of cases,
pointing to a possible disturbance of circadian
rhythms.23 The circadian system comprises three
key components: endogenous oscillators (clocks)
generating a circadian rhythm, input pathways
entraining the circadian rhythm to the astrophysical
day, and output pathways distributing signals from
the oscillator to the periphery. Animal models suggest
a possible role of circadian rhythm genes in ADHD
symptoms via regulation of acetylcholine release in
the hippocampus, which is associated with attention,
learning and memory.24
To further investigate genes previously associated
with ADHD and extend the analysis to additional
candidate genes, we completed an in depth analysis
of 51 genes in a European multisite sample of ADHD
combined type probands, siblings and parents. The
study used the first set of 674 families collected for
the International Multisite ADHD Gene project (the
IMAGE project). We selected high priority candidate
genes on the basis of prior evidence from pharmaco-
logical, neurobiological and genetic investigations.25
By taking a ‘biological systems’ approach to candidate
gene selection, including the most promising genes
identified so far, we aimed to maximise our chances
of detecting multiple associations with genes known
or hypothesised to participate in the regulation of
neurotransmitters pathways (dopamine, norepinephr-
ine and serotonin), and circadian rhythms. We aimed
to take advantage of contemporary high-density
SNP maps to provide a comprehensive coverage of
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each gene, by screening both tagging SNPs selected
from HapMap,26 and SNPs within known functional
regions.
Subjects and methods
Subjects and sample collection
European Caucasian subjects were recruited from 12
specialist centres in eight countries: Belgium, Ger-
many, Holland, Ireland, Israel, Spain, Switzerland
and United Kingdom. Ethical approval for the study
was obtained from National Institute of Health
registered ethical review boards for each centre.
Detailed information sheets were provided and
informed consent obtained from the majority of
children and from all of their parents. All ADHD
probands and their siblings were aged 5–17 years at
the time of entry into the study and access was
required to one or both biological parents for DNA
collection. Entry criteria for probands were a clinical
diagnosis of DSM-IV combined subtype ADHD
and having one or more full siblings available for
ascertainment of clinical information and DNA
collection. Exclusion criteria applying to both pro-
bands and siblings include autism, epilepsy, IQ < 70,
brain disorders and any genetic or medical disorder
associated with externalising behaviours that might
mimic ADHD.
The final data set used in this study consisted of
674 DSM-IV combined type probands with 808
siblings. One hundred and two of the siblings also
had combined type ADHD making a total data set of
776 affected individuals. DNA was available for both
parents in 614 families (90%) and from one parent in
49 families (7%). 93.5% of the ADHD cases were male
subjects. The age range for both probands and siblings
ranged from 5 to 17 years with the mean age of
11.2 (s.d. = 2.7) for probands and 11.2 (s.d. = 3.1) for
siblings.
Since we evaluated all available siblings (n = 808),
including a set of DSM-IV combined type ADHD cases
(n = 102), we estimated the ls value for DSM-IV
combined subtype to be around five using the
population prevalence of 0.024 estimated from a
recent survey in the United Kingdom.27 Prior to entry
into the study, all probands underwent clinical
evaluations by a paediatrician or child psychiatrist
and both existing and new patients were included in
the study. Wherever possible, families withdrew
stimulant medication for 1 week prior to research
assessments to allow for more accurate ascertainment
of the current level of ADHD symptoms and behaviours.
Alternatively, we ensured as far as possible that
ratings were based on medication-free periods. Pro-
bands were excluded from the study if the last
medication free period was more than 2 years ago.
Clinical procedures
Parental account of childhood symptoms (PACS). PACS
is a semistructured, standardised, investigator-based
interview developed as an instrument to provide an
objective measure of child behaviour.28 A trained
interviewer administers PACS with parents, who are
asked for detailed descriptions of the child’s typical
behaviour in a range of specified situations. Such
situations are defined either by external events (e.g.
watching television, reading a book or comic, playing
alone, playing with friends, going to bed, traveling)
or by behaviours shown (e.g. crying, worried talk,
tempers, fighting with siblings). Interviewers then
make their own ratings on the basis of a formal
training and written definitions of the behaviours to
be rated, on a four-point scale of severity and
frequency in the previous week and previous year.
Inter-rater reliability is high with product-moment
correlations for pairs of interviewers ranging
from 0.79 to 0.96. The Hyperactivity Subscale is
made up of attention span (time spent on a single
activity, rated separately for four different kinds of
activity), restlessness (moving about during the same
activities), fidgetiness (movements of parts of the
body during the same activities), and activity level
(rated for structured situations such as mealtimes and
car journeys), with other subscales covering defiant,
emotional and other comorbid disorders including
autistic spectrum disorders.
Rating scales. Rating scales used to quantify ADHD
symptoms included the Long Version of Conners’
Parent Rating Scale (CPRS-R:L), Long Version
of Conners’ Teacher Rating Scale (CTRS-R:L),29
parent version of the Strengths and Difficulties
Questionnaires (SDQ) and teacher version of SDQ.30
In order to exclude autism spectrum disorders that
might confound the analysis of ADHD, both probands
and siblings were screened using the Social
Communication Questionnaire (X15) in conjunction
with the pro-social scale from the SDQ (p4).
Individuals falling above these thresholds were
further evaluated using the autism spectrum
disorder section of the PACS interview.
DSM-IV diagnoses. All raw data is centralised and
stored on a secure database at the MRC Social Genetic
Developmental Psychiatry research centre in London.
A standardised algorithm is applied to PACS to
derive each of the 18 DSM-IV ADHD items, pro-
viding operational definitions for each behavioural
symptom. These are combined with items that scored
2 or 3 from the teacher rated Conners’ ADHD
subscale, to generate the total number of items
from the DSM-IV symptom checklist. Situational
pervasiveness was defined as some symptoms
occurring within two or more different situations
from the PACS interview, as well as the presence of
one or more symptoms scoring 2 or more from the
ADHD subscale of the teacher rated Conners’. Other
ADHD symptom scales and measures of co-morbidity
were not used in the diagnostic algorithm for the
analyses in this paper.
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DNA collection and genotype assays. Blood samples
were sent immediately following collection by an
International Courier service to Rutgers University
Cell and DNA repository, New Jersey (RUCDR). These
were either used to generate lymphocyte cell lines
from which DNA was extracted, or DNA was extracted
directly from a portion of the blood sample and
lymphocytes cryopreserved for future recovery. In a
few cases where individuals were not able to supply a
blood sample, we used a mouth swab sampling
technique and extracted the DNA at the SGDP
laboratories in London. DNA stocks for the entire
data set were collated in London where they were
stored, organised and plated out for further analysis.
Geneservice Ltd, Cambridge (UK) performed whole-
genome amplification on all samples with < 100mg
stock DNA, using the REPLI-g kit (Quiagen Ltd,
Crawley, UK). DNA samples were arrayed into 96-
well plates at a concentration of 50 ng/ml and
delivered to Illumina Inc. (San Diego, USA) under
dry ice. In addition to the IMAGE sample, we
included the panel of 30 CEPH trios of Northern
European ancestry used in the HapMap project.26
All the SNP genotype assays were completed on a
custom array using the Illumina Golden Gate AssayTM
(Illumina Inc., San Diego, USA). In addition, we
included the analysis of VNTR polymorphisms from
exon three of the DRD4, the 30-untranlsated region
and intron 8 of the DAT1, and promotor region of the
serotonin transporter (SERT) genes, which had pre-
viously been associated with ADHD.8,28 Standard PCR
protocols were used for all VNTR markers and
amplified products visualised on 2% agarose under
UV light, as previously described.31–33
SNP selection
We adopted a ‘biological systems’ approach by
nominating 46 genes that were likely to exert an
effect through regulation of dopamine, serotonin and
norepinephrine neurotransmission, as well as six
circadian rhythm genes. Selected genes fell into the
following functional groups: dopamine receptors,
serotonin receptors, norepinephrine receptors, neuro-
transmitter metabolic and catabolic enzymes, neuro-
nal transporters, synaptic vesicle associated proteins,
fatty acid desaturase enzymes and circadian rhythm
genes (listed in Table 1). The selected genes included
23 that had previously been reported to contain
polymorphic variants associated with ADHD in one
or more studies, in addition to 28 genes that have yet
to be investigated in ADHD or had not shown an
association signal in previous studies.
For SNP selection we aimed at a comprehensive
analysis of each gene using two main approaches.
First, the direct association analysis of SNPs that fall
in functional regions and have an increased chance of
functional significance by virtue of their location. For
this approach we targeted SNPs located within coding
regions (synonymous and nonsynonymous), 50 and 30
untranslated regions, intron sequences within 300 bp
from intron/exon boundaries, and one SNP per kb
covering 5 kb upstream from the start of transcription
or known 50 regulatory regions including the promo-
tor.
Second, we aimed to use indirect association to
screen for association with common genetic variation
across each gene. For this method we targeted a
nonredundant set of tagging SNPs (tSNPs) that
correlated highly with SNPs with minor allele
frequency (MAF) X0.05, using the CEPH panel from
the HapMap database. We selected tSNPs using two
methods. We used the ‘CompleteLink routine’ within
CLUSTAG that implements a hierarchical clustering
algorithm (http://hkumath.hku.hk/web/link/CLUS-
TAG/CLUSTAG.html.34 Hierarchical clustering starts
with a square matrix of pair-wise distances (as
defined by 1-R2) between the SNPs to be clustered.
The rationale is that the noncentrality parameter
(NCP) for a tSNP is the product of the NCP at the
causal SNP and the R2. In order to ensure a high
chance of detecting indirect association, we used a
threshold for R2 of X0.8. The second method used
for tSNP selection was the default algorithm in
Haploview (http://www.broad.mit.edu/mpg/haplo-
view) taken from Gabriel et al. (2002).35 95%
confidence bounds on D-prime are generated and
each comparison is called ‘strong LD’, ‘inconclusive’
or ‘strong recombination’. A block is created if 95%
of informative comparisons fall in the ‘strong
LD’ category. The default setting for this algorithm
sorts the list of all possible blocks, starting with the
largest and adding blocks as long as they don’t
overlap with an already declared block. 39.6% (132
out of 437 tSNPs) of the CLUSTAG SNPs and 71.8%
(241 out of 437 tSNPs) of the Gabriel method SNPs
were shared. 7.0% (77 out of 1105, functional SNPs)
were included in the tSNP criteria. To avoid redun-
dancy of the marker information, where the two
methods recommended selection of two different
SNPs that fell within the same cluster defined by
CLUSTAG, we preferentially selected the tSNP re-
commended by the CLUSTAG algorithm. If due to the
constraints of the Illumina technology the tSNPs
nominated by CLUSTAG could not be genotyped an
alternative SNP located in the same cluster was
selected.
SNP genotyping was completed using the Illumina
high-throughput BeadArrayt technology (http://
www.illumina.com). This set limits on the SNP
selection, based on estimates from Illumina of the
genotype success rate for each SNP. Data supplied by
Illumina included a list of SNPs and their estimated
genotype success rate for each gene, with an overall
estimate of ‘success rate’ that takes into account both
SNP validation status and designability for the array
platform. In addition, markers less than 60 bp apart
could not both be genotyped; when this occurred we
selected the SNP with the highest estimation of
overall success rate, followed by highest MAF. For
tSNPs selected from HapMap, there were often
additional SNPs that fell within a SNP cluster that
could be selected in preference to one with a low
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estimate of success rate. We set a lower limit for MAF
of 0.05; however, we included a high proportion of
nonvalidated SNPs and SNPs with unknown hetero-
zygosity from ‘functional’ regions.
We grouped the selection criteria for SNPs as
follows: Group 1 consisted of SNPs with known
heterozygosity and previously genotyped on the
Illumina platform; Group 2 consisted of SNPs with
Table 1 The majority of genes to be included in this SNP screen have previously been investigated in relation to ADHD
Gene Replication
status
Location
(Chr)
Length
(kb)
No. of
SNPs
SNP density
(SNPs/kb)
No. of SNPs
(tagging)
No. of SNPs
(functional)
ADRA1A 0 8p21 117.3 41 2.86 17 24
ADRA1B 0 5q33 60.8 15 4.05 7 8
ADRA2A þ 10q24 8.6 9 0.96 1 8
ADRA2C þ 4p16 7.8 7 1.11 1 6
ADRB1 0 10q24 1.7 4 0.43 2 2
ADRB2 0 5q32 2 11 0.18 4 7
ADRB3 0 8p12 3.7 8 0.46 0 8
ADRBK1 0 11q13 20.2 7 2.89 4 3
ADRBK2 0 22q11 159 16 9.94 7 9
ARRB1 0 11q13 23.9 13 1.84 6 7
ARRB2 0 17p13 11 6 1.83 2 4
BDNF þ 11p13 71.8 20 3.59 8 16
CHRNA4 þ 20q13 21.7 19 1.14 5 15
COMT þ 22q11 32.2 30 1.07 8 22
CSNK1E 0 22q12 31.8 17 1.87 10 8
DBH þ 9q34 28 33 0.85 18 15
DDC þ 11p17 90.7 41 2.21 19 22
DRD1 þ 5q31 81.2 11 7.38 3 8
DRD1IP þ 10q26 16.5 6 2.75 4 3
DRD2 þ 11q23 70.5 23 3.07 11 12
DRD3  3q13 55.2 28 1.97 9 19
DRD4 þ 11p15 8.4 4 2.10 1 3
FADS1  11q12 17.2 7 2.46 2 7
FADS2 þ 11q12 44.1 19 2.32 11 12
HES1 0 3q28 5.2 5 1.04 3 2
HES6 0 2q37 12.5 4 3.13 4 0
HTR1B þ 6q13 6.2 11 0.56 5 7
HTR1E 0 6q14 84 20 4.20 14 11
HTR2A þ 13q14 67.7 32 2.12 22 13
HTR3B 0 11q23 46.7 15 3.11 6 12
NET1 þ 16q12 16.8 43 0.39 13 34
NFIL3 0 9q22 1.8 6 0.30 5 1
NURR1 0 2q22 15 6 2.50 5 4
PER1 0 17p12 4 13 0.31 8 5
PER2 0 2q37 48.7 19 2.56 8 13
PNMT þ 17q21 2.2 2 1.10 0 2
VMAT2  10q25 41.4 30 1.38 10 23
SLC6A1 0 3p25 51.5 35 1.47 16 22
DAT þ 5p15 57.6 32 1.80 12 27
SERT þ 17q11 42.8 14 3.06 7 9
SLC9A9 0 3q21 588.2 70 8.40 122 62
SNAP25 þ 20p11 93.6 98 0.96 20 22
STX1A  7q11 14.9 38 0.39 4 8
SYT1  12cen 238.5 9 26.5 18 17
TPH1  11p15 24.8 14 1.77 5 9
TPH2 þ 12q15 98.6 40 2.47 11 29
VAMP2  17p12 8.8 5 1.76 0 5
HTR2C þ Xp24 331 23 14.39 0 23
MAOA þ Xp11 95.6 16 5.98 0 16
MAOB  Xp11 120.8 10 12.08 0 10
SYP þ Xp11 17.4 1 17.4 0 1
Replication status: ‘0’ = not previously investigated; ‘þ ’ = previous positive association reported; ‘’ = previous negative
association reported. We investigated a total of 925 SNPs with minor allele frequency X0.02, spanning a total region of
3.121 kb with an average SNP density of 1 SNP every 3.4 kb.
ADHD, attention deficit hyperactivity disorder; SNP, single-nucleotide polymorphism.
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known heterozygosity but not genotyped previously
on the Illumina platform; Group 3 consisted of SNPs
validated by proven 2hit-2-allele (every allele has
been observed in at least two chromosomes; Group 4
consisted of other SNPs at various levels of valida-
tion. Illumina provided estimates of overall success
on their platform: with a high designability rating
Group 1 SNPs had a 90–95% success rate, Group 2 a
80–85% success rate, Group 3 a 30–50% success rate,
and Group 4 an unknown success rate.
Of the 1536 SNPs included in the SNP array, there
were 173 assays that completely failed across all
samples. An additional 34 SNP assays failed only in
the whole-genome amplified (WGA) DNA. Remaining
genotypes from WGA DNA had similar genotype
error, heterozygosity values and Hardy–Weinberg
Equilibrium (HWE) distribution to nonamplified
DNA, indicating a failure of the WGA method to
amplify approximately 2% of loci, but no apparent
allelic drop out or loss of quality compared to
nonamplified DNA. GenCall quality control scores
supplied by Illumina were higher than 0.25 in
99.78%, indicating a high average quality score with
no samples dropping below the recommended quality
control threshold of 0.2–0.25. As expected, SNP
MAFs varied within the various validity groups used
for selection of the remaining 1363 SNPs: MAF X5%
were found in 88% of Group I SNPs, 86% of Group 2
SNPs, 21% of group 3 SNPs, and 20% of Group 4
SNPs. Using NCBI validation criteria (proven by
cluster; proven by frequency; proven by submitter;
proven by 2hit-2allele), 75.7% had MAFX2% and
70.2% MAFX5%, whereas for NCBI nonvalidated
SNPs only 16.4 and 11.3% were polymorphic at the
same MAF thresholds. The overall success rate was
925 (67.1%) SNPS with MAFX, and 860 (63.1%) with
MAFX5%.
Pedigree error checks
Ten samples out of the total of 2937 samples
( < 0.04%) could not be genotyped even after multiple
attempts and were removed from the data set. For the
remaining samples (not including the 34 markers that
failed on the WGA DNA) the average genotype drop
out rate was 0.02%.
To investigate the random genotyping error rate, we
included 15 duplicate DNA samples in the screening
panel, which produced more than 40 000 genotype
calls (1,363). All the duplicated genotypes were 100%
consistent and the random genotyping error rate
could therefore be estimated as lower than 0.005%
(1/20 000). To investigate the systematic genotyping
error rate on the Illumina platform, 30 CEPH trios
screened in the HapMap project were also genotyped
using our SNP panel. By comparison of 879 SNPs
genotyped in both projects, there were 0.12% (92 out
of 77 871) genotype inconsistencies. Since more than
95% of the HAPMAP genotypic data were not
replicated on different platforms we estimate that
half of the inconsistencies (0.06%) are due to
systemic errors on our platform. The overall geno-
typing error (sum of the random and systematic
error rates) would therefore be lower than 0.065%
(0.06þ0.005).
By running PEDCHECK for single point Mendelian
inconsistencies on 987 polymorphic autosomal mar-
kers in the initial data set of 680 families, we
identified 47 families with potential pedigree errors.
Within these families the numbers of Mendelian
errors range from 16 to 312 and could not be
explained by genotyping errors. To identify the real
problem of these pedigree errors which might be DNA
swap, nonreported non paternity, nonreported half-
sibs or any other unexpected errors, we performed the
following steps and checked the reduction of Mende-
lian errors after each step: (1) Randomly assign any
two subjects from a family as parents. (2) Drop one
subject at a time from a family. (3) Insert erroneous
subjects back to any empty place left by step 2. Using
this procedure we identified 16 DNA swaps, eight
nonpaternity and seven half-sib cases, which cleared
up the Mendelian errors from 40 families. This left
seven families with unknown pedigree errors that we
removed from the analysis. The final data set for
association analysis included 674 families that con-
tained 156 sporadic Mendelian errors from 987
autosomal markers. The overall detection rate of
Mendelian errors is therefore 0.02%, which is con-
sistent with the estimated efficiency of SNP markers
(13–75%, to detect such errors by identification of
Mendelian errors and an estimated overall genotype
error rate less than 0.065%). The large number of
pedigree errors may be explained by the complicated
procedures inherent within a large international
cooperative process.
Hardy–Weinberg equilibrium (HWE)
We tested HWE in all common SNPs (MAFX0.05)
using Pedstats. HWE tests were performed on groups
consisting of IMAGE parents and offspring. Overall
we identified 16 SNPs in the parent group, and 35
SNPs in the offspring group, with HWE P < 0.01. Two
of these SNPs were shared across the two groups and
were removed from the analysis. One possible
explanation for the increased rate of HW disequili-
brium in the offspring is that association is con-
founded with the HWE test (Supplementary Table 1).
Association tests
The main analyses used transmission disequilibrium
tests (TDT) implemented using the UNPHASED
www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased)
and WHAP (www.genome.wi.mit.edu/~shaun/whap)
programs.
Single marker tests of association. For single marker
analysis, we used a nominal approach, and two
permutation tests to adjust for various multiple
testing issues at the gene-wide level.36 Although the
processes of using more than one main statistic could
create an additional multiple-testing problem, we
consider that the increased level of information,
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provides fuller knowledge of the association signal
within each gene:
(1) Nominal P-values: Nominal P-values were ob-
tained using different implementations of the TDT
test in UNPHASED and WHAP. UNPHASED has
the advantage of generating transmission ratios
for each SNP and handles both autosomal and
X-chromosome markers. Significance values cal-
culated by UNPHASED was used to rank order the
genes on the basis of the most significant SNP
within each gene. WHAP was used as a secondary
test to provide additional information about the
association signal and confirmation that both
methods worked properly; but does not handle
X-chromosome markers. Significance values in
WHAP are empirically derived by permutation
and are therefore robust to asymptotic theory. We
used 500 permutations of the data and 5,000
permutations for P-values < 0.05.
(2) Global-P: For each gene, we derived the maximum
SNP association from UNPHASED, adjusted for
all SNPs within each gene. Global-P-values are
determined in UNPHASED to compare the max-
imum observed SNP score in the observed data
against each maximum of the SNP score in the
permuted data set.
(3) P-SUM values: We derived the global evidence for
association across each gene by summation of SNP
P-values across each gene. P-SUM values were
determined using WHAP to compare the sum of P-
values for all SNPs within each gene, with the
sum of the observed scores in the permuted data
set. P-SUM significance levels may therefore
reflect either single or multiple clusters of asso-
ciated SNPs across a gene.
Multimarker tests of association. We decided a priori
to restrict haplotype analyses to the investigation of
genes that showed evidence for association with
single SNP markers, in order to minimise type I
error arising from performing multiple tests. We
therefore restricted ourselves to genes that contained
one or more SNPs achieving nominal significance
(P < 0.05). The overall aim of these analyses was to use
these data to delineate as far as possible the putative
associated regions.
For haplotype considerations, we adopted two
main approaches. We applied the default block
definition in HAPLOVIEW (http://www.broad.mit.
edu/mpg/haploview) using the method of Gabriel
et al.35 In this method 95% confidence bounds on D
prime are generated for each pair-wise comparison.
An SNP block is formed if 95% of informative
comparisons are in ‘strong LD’. Although this method
allows for multiple overlapping blocks, the default
method is to identify the largest blocks and to avoid
overlapping blocks. Haplotype tests of association
were run using the UNPHASED program on blocks of
SNP markers identified in HAPLOVIEW. To explore
the data further, we were also interested to establish
whether the analysis of consecutive SNPs that may
not always be in strong LD with each other, could
provide additional information. For this analysis we
calculated 5-SNP haplotype associations using the
sliding window method implemented in the WHAP
program.
Results
The final data set consisted of 674 families with 776
affected individuals with DSM-IV combined subtype
ADHD of which 598 (88.7%) of families had both
parents, 73 (10.83%) had only one parent, and three
(0.45%) had no parents. A summary of the final
set of genes and SNPs used in this analysis is listed
in Table 1.
Single marker analyses
A summary of the maximum significance values for
each gene is provided in Figure 1 (detailed summary
of P-values from UNPHASED and WHAP in online
Supplementary Tables 2a, b and 3) and for the most
significant genes with nominal P-values p0.05 in
Table 2. We identified six genes with nominal
significant SNP scores p0.01 and an additional 12
genes with nominal significant scores > 0.01 and
p0.05. Using the Global-P gene-wide test of associa-
tion, we identified three genes with Global-P-values
p0.1 (ADRB2, HES1, MAOA) and three additional
genes with Global-P-values p0.05 (TPH2, ARRB2,
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Figure 1 Maximum unadjusted P-values for each gene. Genes are listed in map order chromosome 1 through the X
chromosome. Genes with one or more SNPs with nominal P-values < 0.05 are labelled.
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SYP). Using the P-SUM gene-wide test the most
significant genes were DAT1 (P < 0.02), PNMT
(P < 0.03), HES1 (P < 0.1) and TPH2 (P = 0.1).
We investigated a total of 925 SNPS with MAF
X2% and would expect 46 SNPs at the 0.05 level
and nine SNPs at the 0.01 level whereas we observed
51 SNPs and 12 SNPs at each significance value
respectively. Although numerically greater than
expectation, the overall distribution of P-values was
not significantly increased from expectation. To
quantify the probability that we had detected one or
more true findings, we ranked the nominal P-values
from the UNPHASED analysis and applied a false
discovery rate of 50%. This identified 10 SNP
markers that fell within three genes; TPH2, DAT1
and ARRB2.
Haplotype analyses
The results of the haplotypes tests using the Gabriel
method to define haplotype blocks and the sliding
window approach are summarised in Table 3,
Figure 2 and Supplementary Tables 4 and 5. Using
the Gabriel method, we find nominal evidence
for association with ARDRB2 (P < 0.002), SNAP-25
(P < 0.004) and TPH2 (P < 0.01). Using the 5-SNP
sliding window, we find nominal evidence for
association with CHRNA4 (P < 0.05), HTR1A
(P < 0.03), PER2 (P < 0.04), NET1 (P < 0.005), TPH2
(P < 0.01), ADRB2 (P < 0.03) and MAOA (P < 0.04). The
majority of haplotype window associations contained
SNPs that were significant when considered on their
own. Two additional associations were identified
with haplotype windows in NET1 and CHRNA4 that
Table 2 Table of results for the 18 genes found to be suggestive of association in the SNP screen
Gene Nominal T NT OR Global P_SUM
P-value P-value Statistic
TPH2 0.003 207 151 1.37 0.036 0.106
ARRB2 0.004 103 66 1.56 0.022 0.209
DAT1 0.005 349 278 1.26 0.119 0.014
PNMT 0.008 70 42 1.67 0.012 0.024
SLC9A9 0.01 74 46 1.61 0.485 0.114
NET 0.012 133 95 1.4 0.349 0.786
ADRB2 0.013 210 162 1.3 0.088 0.485
HES1 0.016 300 244 1.23 0.076 0.096
ADRA1A 0.017 283 229 1.24 0.443 0.387
PER2 0.017 31 15 2.07 0.124 0.419
MAOA 0.02 175 134 1.31 0.082 —
SNAP25 0.035 155 120 1.29 0.529 0.198
DDC 0.039 161 126 1.28 0.537 0.597
FADS2 0.039 284 237 1.2 0.389 0.727
SYP 0.045 180 114 1.25 0.034 —
CHRNA4 0.05 116 88 1.32 0.503 0.663
HTR1E 0.051 75 53 1.42 0.509 0.214
DRD4 0.055 34 20 1.7 0.199 0.321
Nominal P-value is the most significant SNP from UNPHASED analysis with the relevant number of transmitted (T) and
nontransmitted (NT) alleles from heterozygote parents. Odds ratios (OR) and the significance values for the two gene-wide
association tests are listed (Global-P and P-SUM). P-SUM could not be calculate for X-chromosome markers
Table 3 Haplotype analysis using 5-SNP sliding window method and analysed using UNPHASED
Gene Marker Window P-value T NT OR Haplotype-specific
P-value
NET1 16-17-18-19-20 0.005 119 95 1.25 0.101
TPH2 36-37-38-39-40 0.007 206 151 1.36 0.004
PER2 3-4-5-6-7 0.016 188 160 1.18 0.133
ADRB2 4-5-6-7-8 0.024 137 98 1.40 0.011
HTR1E 9-10-11-12-13 0.031 15 8 1.88 0.144
MAOA 12-13-14-15-16 0.033 167 133 1.26 0.050
CHRNA4 11-12-13-14-15 0.046 14 3 7.12 0.008
Genes are ranked by nominal P-value (P < 0.05) for the most significant haplotype block within each gene. SNP marker codes
are available from Supplementary Table 2.
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contained no SNPs that had displayed evidence for
association in the single marker tests.
Analysis of gene regions associated with ADHD
We identified 18 genes that show nominal evidence of
association with ADHD from our SNP screen of 674
ADHD families (Table 2). These genes can be divided
into three groups; those that have been replicated two
or more times, those that have had single reports of
association and those that are novel findings. For this
purpose we assume that SNP replications should be
allele or haplotype specific, since other scenarios are
less likely to reflect true associations. These data and
the match to our significant SNPs are summarised in
Table 4.
Our SNP panel failed to assay some of the SNPs
reported to be associated with ADHD in previous
studies. For those SNPs that had been genotyped in
the HapMap project, the LD maps generated from
genotyping our custom SNP array on the HapMap
Caucasian CEPH panel, were used to identify a SNP
in our panel that acted as a reasonable proxy for
indirect association. For this purpose, we integrated
our CEPH panel genotypes with those from the
HapMap PHASE I data release (Oct 2005) and built
an LD map with 1947 additional SNPs within the
genomic regions of our scan. In a few cases we were not
able to clearly establish the identity of SNPs reported
in the literature due to differences in nomenclature.
Multiple reports group
The first group contains genetic associations that have
been reported two or more times in the ADHD
literature. These genes include DAT1, NET1, DRD4,
MAOA and SNAP25.
DAT1
A finding that has been widely reported is the
association between ADHD and the 10-repeat allele
of a VNTR in the 30UTR region of DAT1. A
nonsignificant overtransmission from heterozygote
parents to their affected offspring was observed
(allele-specific P = 0.21), with an odds ratio
(OR = 0.11) very close to the OR (1.12) estimated in a
recent meta-analysis of available data.8 More recently
investigation of genetic variation in DAT1 in English
and Taiwanese samples suggested that the association
is specific to a haplotype of the 10-repeat allele, with
the 3-repeat allele of a second VNTR located within
intron 8.31 Analysis of these two markers in this
sample revealed the same pattern, with only the 10-3
haplotype showing over transmission from hetero-
zygote parents to their affected offspring (haplotype
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Figure 2 5-SNP sliding window haplotype analysis using UNPHASED (log P-values), for seven genes with nominal
haplotype P-values < 0.05. Sliding Windows run 50 to 30 in SNP order. The window numbers are the same as the number of
the first SNP within each 5-SNP set. SNP numbers for each gene can be found on online Supplementary Table 2.
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Table 4 Table of literature findings for the 18 genes with one or more SNPs with nominal Pp0.05 from this study
Paper Gene Polymorphism Location Finding in
literature
SNP
array
Finding from this study
Sheehan et al.53 TPH2 rs1843809 Intron 5 T-allele Y Positive but with opposite
allele
rs1386493 Intron 5 C-allele Y Positive but with opposite
allele
rs1386497 Intron 8 A-allele N Clusters with rs1007023
(r2 = 1): Positive
rs2129572 Intron 4 NS N
rs1023990 Intron 7 NS N Clusters with rs1386491
(r2 = 0.9): Negative
rs1487278 Intron 8 NS N
rs1487275 Intron 8 NS Y Negative
rs1487279 Intron 9 NS N
Walitza et al.54 rs4570625 Promoter
(703)
G-allele Y Negative
rs11178997 Promoter
(473)
T-allele N
rs4565946 Intron 2 NS N Clusters with rs4448731
(r2 = 0.9): Negative
Brookes et al.21 SYP rs2293945 30UTR Positive N
Brookes et al.55 FADS rs498793 Intron 6 Positive Y Negative
Mill et al.50,51 SNAP25 Microsatellite Intron 1 Positive —
TG repeat Promoter Positive —
A-2015T Promoter A-allele N
G80609A Intron 7 G-allele N
rs3746544 30UTR T-T-haplotype N
rs1051312 30UTR T-T-haplotype N
Brophy et al.47 rs3746544 30UTR NS N
rs1051312 30UTR T-allele N
Barr et al.48 rs3746544 30UTR T-allele (T-C
haplotype)
N
rs1051312 30UTR C-allele (T-C
haplotype)
N
Kustanovich
et al.49
rs3746544 30UTR T-allele N
rs1051312 30UTR T-C haplotype N
Kim et al.
(unpublished)
rs3787283 Intron 6 Positive Y Negative
rs2327269 outside gene Positive N
Feng et al.63 rs6039806 Intron 2 C-allele Y Negative
rs362549 Intron 4 A-allele N
rs362987 Intron 4 A-allele Y Negative
rs362998 Exon 5 aa 110 C-allele N
rs1889189 50 to gene NS Y Negative
rs362569 50UTR NS N Clusters with rs6039806
(r2 = 0.76): Negative
rs362549 Intron 3 NS N Clusters with rs362987
(r2 = 0.84): Negative
rs362986 Intron 4 NS N
rs363006 Intron 6 NS Y Negative
rs3746544 30UTR NS N
rs1051312 30UTR NS N
Bobb et al.38 Microsatellite 50UTR NS —
Domschke et al.44 MAOA 30 bp repeat Promoter Positive
(short-allele)
—
CA repeat Intron 2 Positive —
G941T Exon 8 G-allele —
A/G Intron 12 NS —
Xu et al.42 NET rs3785157 Intron 7 G-allele N Clusters with rs1861647
(r2 = 0.93): Negative
rs2242447 Intron 13 T-allele (trend) Y Negative
rs998424 Intron 9 g-allele (trend) N
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Table 4 Continued
Paper Gene Polymorphism Location Finding in
literature
SNP
array
Finding from this study
Bobb et al.38 rs998424 Intron 9 G-allele N
rs3785157 Intron 7 T-allele N Clusters with rs1861647
(r2 = 0.93): Negative
Barr et al.64 SNP Exon 9 NS N
rs998424 Intron 9 NS N
rs2242447 Intron 13 NS Y Negative
McEvoy et al.65 C1148A Intron 7 NS —
G1389A Intron 9 NS —
Comings et al.66 A1970G SNP Positive —
De Luca67 G1389A Intron 9 NS —
Kent et al.68 CHRNA4 Cfol SNP Exon 5 Positive —
Bobb et al.38 rs6090384 Intron 1 or 2 NS Y Negative
rs2273505 Intron 1 or 2 NS N
rs2273506 Exon 1 or 2 NS Y Negative
Comings et al.69 Dinucleotide Intron 1 Positive —
Todd et al.70 SNP 50 Intron 2 Positive
(Inattent)
—
Hawi et al.39 DAT rs6347 Exon 9 P = 0.22 Y Positive with WHAP: A-allele
rs11564774 Exon 15 P = 0.7 N
Brookes et al.31 rs40184 30UTR P = 0.22 Y Positive G-allele
rs1042098 30UTR P = 0.121 Y Positive A-allele
rs27072 30UTR P = 0.28 Y Trend with WHAP G-allele
VNTR 2 30UTR-intron 8 10-3 haplotype — Positive
Feng et al.37 rs27072 30UTR G-allele Y Trend with WHAP G-allele
rs8179029 Intron 9 NS Y Negative
rs3863145 30UTR NS N
Bobb et al.38 rs6347 Exon 9 A-allele
(trend)
Y Positive with WHAP A-allele
Rowe et al.71 DRD2 Taq1 Positive —
Comings et al.72,73 Taq1 Positive —
Todd and Lobos
et al.74
Screened NS —
Huang et al.75 Taq1 NS —
Muglia et al.76 DRD3 Ser/Gly Exon 1 NS —
Payton et al.56 A/G Exon 1 NS —
Barr et al.77 Ser/Gly Exon 1 NS —
MspI Intron 5 NS —
Lowe et al.40 DRD4 rs1800955 Promoter A-allele N
rs747302 Promoter C-allele N
rs910455 Promoter NS N
Payton et al.56 rs1800955 Promoter NS N
Bellgrove et al.41 rs1800955 Promoter A-allele N
Barr et al.62 rs1800955 Promoter A-trend N
rs747302 Promoter C-trend N
Hawi et al.57 DDC 4 bp insertion Exon 1 Trend —
Microsatellite 30 P = 0.04 —
Haplotype P = 0.025 —
Microsatellite 50 NS —
Comings et al.78 DBH Taq1 Intron 5 NS —
Daly et al.79 Taq1 Intron 5 A2-allele —
Wigg et al.80 Taq1 Intron 5 A2-allele
(trend)
—
Roman et al.81 Taq1 Intron 5 A2-allele —
Inkster et al.82 Taq1 Intron 5 A2-allele
(trend)
—
Smith et al.83 Taq1 Intron 5 A1-allele —
Zhang et al.84 C-1021T Promoter Trend —
Zhang et al.85 C-1021T Promoter Positive —
Eisenberg et al.86 COMT rs4680 Exon 2 aa 158 Positive (Val) Y Negative
Qian et al.87 rs4680 Exon 2 aa 158 Positive (Met) Y Negative
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specific P < 0.06, OR = 1.19); consistent with the 10-3
haplotype association in the previous study.
Two SNPs have been highlighted in earlier studies;
rs2707234 and rs6347.38,39 We detected a trend with
over transmission of the same allele (A-allele) in
rs6347 and no association with rs27072. We did
however detect additional evidence for association in
the 30UTR, intron 10 and intron 13. LD between the
associated SNPs was generally weak with the stron-
gest relationship between rs1042098 and rs3776513
(r2 = 0.378). One of the associated SNPs (rs40184)
shows some LD with rs27072 (r2 = 0.274).
No positive findings of association have been
reported in the published literature with SNPs in
the 50 flanking region. We observed four SNPs in this
region with P < 0.05. Three of the associated SNPs
(rs2652511, rs10070282 and rs2550946) show very
strong LD with an average R2 around 0.97, while
rs11564750 shows weak LD with this 3-SNP cluster
(R2 approximately 0.14).
DRD4
Numerous studies have investigated the association
between ADHD and the 7-repeat allele of a highly
variable VNTR in exon 3 of DRD4. We also detected
overtransmission of this allele from heterozygote
parents to their affected offspring (allele specific
P < 0.09) with an OR (1.18) that was very close to
the average OR (1.17) estimated in a recent meta-
analysis of available data; consistent with a small but
significant genetic association.
Several additional markers in DRD4 have been
reported to be associated with ADHD including
the A-allele of rs180955 in two independent
studies41,41 and weak evidence for association of the
C-allele of rs747302; both located in the promotor
region. We were unable to genotype these two
markers, but we did observe nominal association
with rs9195457. We have no information on the LD
structure between this marker and the two previously
reported SNPs.
NET1
Two previous studies reported association with two
SNPs (rs998424, rs3785157) in NET1 in addition to a
third SNP (rs2242447) in one of the studies.38,42 We
genotyped rs2242447 and a proxy marker (rs1861647)
for rs3785157 (r2 = 0.84 in CEPH panel). Neither of
these two markers showed evidence for association in
our sample. The SNPs found to be nominally
associated in this study lie within the first
(rs3785143) and fifth (rs11568324) introns and should
be treated as novel findings.
MAOA
Jiang et al.43 using a Chinese sample reported
evidence for association with a dinucleotide repeat
located within intron 2, which was followed by a
Table 4 Continued
Paper Gene Polymorphism Location Finding in
literature
SNP
array
Finding from this study
Bobb et al.38 rs4680 Exon 2 aa 158 NS Y Negative
Thapar et al.88 rs4680 Exon 2 aa 158 Positive (Val) Y Negative
Curran et al.89 SERT rs1050565 exon 12 aa 443 P = 0.0045 N
rs1487871 Intron 3 P = 0.033 N
rs2020930 Not in gene P = 0.035 Y
rs2020937 UTR P = 0.092 N
rs2020942 Intron 1 P = 0.079 Y Negative
rs140701 Intron 7 P = 0.013 Y Negative
T/G SNP 30UTR P = 0.13 —
Kent et al.90 T/G SNP 30UTR T-allele —
Li et al.91 HTR2A rs6313 Exon 1 aa 34 C-allele Y Negative
Bobb et al.38 rs6313 Exon 1 aa 34 NS Y Negative
rs6311 Locus NS Y Negative
rs6314 Exon 3 aa 452 NS Y Negative
Hawi et al.92 HTR1B rs6296 G-allele Y Negative
Quist et al.93 rs6296 G-allele Y Negative
Bobb et al.38 rs6296 Exon 1 aa 287 NS Y Negative
rs6298 Exon 1 aa 43 Trend Y Negative
Li et al.94 rs6296 P = 0.052 Y Negative
Bobb et al.38 HTR2C rs6318 NS Y Negative
Li et al.95 C-759T C-allele —
G-697C G-allele —
The table tabulates the author, reference, gene, rs number is known and gene location. SNP array Y = SNPs included in the
Illumina array. Findings in the literature list nominal significant associations with risk allele identified whether possible,
NS = nonsignificant, positive = significant but associated allele unknown. Findings from this study are listed in the last
column.
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reported trend for association with this marker in an
independent Caucasian sample.44 A 30 bp VNTR with
2–5 repeats in the promotor region that has been
shown to regulate MAOA transcription levels and a
SNP (G941T) in exon 8 have also been studied. Manor
et al.45 found the 4-repeat allele of the VNTR to be
associated (P = 0.036) with preference for maternal
transmission. However, two studies44,46 identified
association with the short alleles of the VNTR and
one with the G-allele of the G941T.44
In our study we found nominal significance with
five SNPs in addition to two SNPs with P < 0.1. The
region containing these SNPs spans approximately
31 kb from intron 5 to the 30UTR with an average r2 of
0.8, suggesting strong LD. This region incorporates
G941T reported in one of the earlier studies and may
therefore reflect the same association signal; however,
we were unable to determine the rs reference number
for that SNP.
SNAP-25
Four studies have implicated the 30UTR region with
the association of two SNPs.47–50 Interpretation of
these data has been difficult with various combina-
tions of alleles found to be significant across the three
studies: T-allele of rs1051312,48 T-C haplotype of
rs1051312 and rs374654449,50 and the T-T haplotype
of the two SNPs.50 We were unable to genotype these
two markers for technical reasons. We did however
investigate two alternative SNPs in the 30UTR and did
not detect an association signal.
Other SNAP25 markers reported to be associated
with ADHD include a SNP in the 50 flanking region
(A-2015T),50 a microsatellite marker in intron 151 and
the G-allele of a SNP in intron 7 (G-80609A).50 More
recently SNP associations were reported with several
SNPs in introns 2 and 4 and exon 5. We included two
of the four associated SNPs reported in this study,
neither of which gave an association signal. We did
however detect one nominally associated cluster
consisting of two SNPs in the 50UTR (rs363020,
rs362567, r2 = 0.95). We were unable to find the
A-2015T SNP on NCBI.
Single report group
The second group contains SNP associations with
ADHD reported once in the literature. This includes
CHRNA4, TPH2, FADS2 and SYP.52–55
CHRNA4
Association between ADHD and CHRNA4 has pre-
viously been reported with two SNPs located in exon
2 and the 50 end of intron 2.52 However, we found no
evidence for association with these two markers
(rs6090384, rs2273506) or from analysis of haplotypes
in the region. The SNP associated in our sample is in
the 50 flanking region and is a novel finding.
TPH2
Sheenan et al.53 reported three single marker associa-
tions in TPH2: the T-allele of rs1843809, the C-allele
of rs1386493 and the A-allele of rs1386497. We found
association to the first two of these markers; however
the risk alleles were not the same in the two studies.
A third marker (rs1007023) that was in perfect LD
(R2 = 1) with rs1386497 in HapMap was associated in
our sample (P = 0.004). Across these four SNPs the
average R2 across the region is greater than 0.8.
Analysis of haplotypes, while nominally significant,
provided no additional evidence for the association.
In addition, we investigated one of two SNPs in the
50-flanking region, reported by Walitza et al.,54 but
found no evidence of association.
SYP and FADS2
Association with two SNPs in SYP (rs2293945) and
FADS2 (rs498793) were reported in an independent
sample of English combined subtype probands;21,55
Only rs498793 in FADS2 could be genotyped on the
Illumina platform and this did not replicate the
earlier finding. The SNP in FADS2 showing nominal
association in this study (rs174611) is located within
intron 7 and shows weak LD with rs498793 (r2 = 0.1 in
CEPH panel of HapMap). The associated SNP in SYP
found in this study (rs5906754) is located in the 50
flanking region, whereas rs2293945 is located in the
30UTR.
DDC
Association to markers of DDC was reported by Hawi
et al.57 who observed increased transmission of a 4 bp
insertion/deletion in exon 1 and the 213 bp allele of a
microsatellite marker (D7S2422) in the 30-end of the
gene.44 The SNP associated in this study (rs11575454)
is located within intron 8; we have no information on
LD between these various markers.
Novel finding group
The third group included HES1, PER2, SLC9A9,
PNMT, ADRA1A, HTR1E, ADRB2 and ARRB2. None
of these findings approach study wide or genome
wide levels of significance, so these should all be
considered as speculative findings of potential
significance until further replication studies have
been completed. Of these, ARRB2 was the strongest
novel finding, with a nominal P < 0.005 and
Global-P < 0.02 with an SNP rs7208257 located in
intron 5.
P-SUM was significant for PNMT though neither
SNP was particularly common (MAFp0.05). The R2
correlation between these two markers was only
0.001, suggesting that association with these two
low frequency SNPs are independent of each other;
despite the two markers being located less than 1 kb
apart at the 50-end of the gene. Haplotype analysis of
these two markers gives a nominal P-value of 0.0016.
Conditional testing of the contribution of each of
these markers to the haplotype association using
WHAP suggested that both loci contribute to the
haplotype association.
SLC9A9 displayed nominally associated SNPs in
several regions across the gene; intron 14 (P < 0.04),
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intron 12 (P < 0.02), intron 6 (P < 0.02), intron 5
(P < 0.03), intron 2 (P < 0.05, and the 5 flanking
regions (P < 0.02). SLC9A9 was the largest gene region
we investigated, spanning a total distance of 578 kb
and including the analysis of 167 SNPs. Although
none of these SNPs were significant when adjusted
for the total number of SNPs investigated in this gene,
we identified a total of 16 SNPs with P < 0.05 and 29
with P < 0.1, compared to the expected number of 8
and 17 SNPs, respectively.
Discussion
We have completed an association screen of 51
candidate genes in a sample of 776 DSM-IV combined
type ADHD subjects and their parents. We aimed to
provide high coverage of each gene by selecting SNPs
within or close to known functional regions, in
addition to selecting a set of tSNPs that characterised
common variation across each gene. Of 1536 SNPs
included in the SNP array, 925 SNPs with low
estimated error rate and MAFX0.02 were included
in the final analysis. In addition, to the analysis of
SNPs, we investigated association with four VNTR
markers that had shown evidence for association from
meta-analytic studies in DRD4, DAT1 and SERT.
We highlighted the most promising associations by
ranking genes on the basis of nominal P-values for the
most significant SNPs within each gene; this identi-
fied 18 genes containing one of more SNPs with a
nominal Pp0.05. We adjusted for testing multiple
SNPs across each gene using two permutation tests;
the global P-value statistic that identified the most
significant SNP adjusting for the number of SNPs in
each gene, and the P-SUM statistic that summarised
the overall evidence for association by summating
P-values across each gene. The permutation tests
provided the best evidence for association with
TPH2 (Global-P = 0.051, P-SUM < 0.1), ARRB2
(Global-P < 0.02), SYP (Global-P < 0.04), DAT1
(Global-P = 0.11, P-SUM < 0.02) and PNMT (Global-
P = 0.02, P-SUM < 0.03). In addition to more marginal
evidence for HES1 (P-SUM < 0.1, Global-P = 0.08),
ADRB2 (Global-P = 0.09), HES1 (Global-P = 0.08) and
MAOA (Global-P = 0.07).
Ten out of the 18 top ranked genes had previously
been reported to show some evidence for association
in previous studies; however, not always with the
same markers or the same alleles. Of particular
interest are the VNTR markers in DAT1 and DRD4
that are both prominent findings in the current
association literature for ADHD. For both of these
genes we found evidence for over transmission of the
previously identified risk alleles, consistent with
small but significant effects. The OR estimated for
these alleles were very close to those established from
meta-analysis, and fits well with expectation from
this relatively large multisite study.
DAT1 was one of the genes for which we had gene-
wide evidence for association using the P-SUM
statistic. For this gene, we found evidence for SNP
associations in three regions of the gene. First, we
detected an association signal (analysed independently
of the two VNTR markers) for SNPs at the 30-end of the
gene. Second, we observed novel evidence for associa-
tion with SNPs in the 50 flanking region. Finally, we
observed marginal evidence for association with
rs6347, a nonsynonymous SNP in exon 9 that showed
weak association in one previous study.96 For both
DAT1 and DRD4 we conclude that small but significant
genetic effects have been demonstrated when these
data are considered alongside the existent literature.
Of the other genes, TPH2 showed a significant
Global-P-value and associated haplotype. The risk
haplotype identified in this study was, however, the
protective haplotype in the previous study from
Sheenan et al.53 further studies will be needed to
clarify the relationship of genetic variants in TPH2
with ADHD. For SYP, FADS2 and DDC, we identified
nominally associated SNPs that did not appear to be
in LD with nominally associated SNPs reported in
previous studies. For NET1 two previous studies
reported weak evidence for association with SNPs in
introns 7 and 9; however, the associated alleles
were different in the two reports and we did not find
evidence for association in this region. We did
however find evidence for association from single
markers and haplotype analysis with SNPs within
the region spanning introns one to five. MAOA is
an interesting gene involved in the catabolism of
catecholamine neurotransmitters with evidence of
extensive LD across the gene locus; we obtained
evidence for association consistent with one previous
report. For SNAP-25 we were not able to replicate
the associations reported to be present at the 30 end
of the gene, but did detect an association signal in
the 50 UTR, consistent with findings reported by
Mill et al.50 Finally, we detected several novel
associations with the strongest evidence coming from
PNMT and SLC9A9, in addition to evidence for
association with two genes in the circadian rhythm
system.
With the exception of DRD4 and DAT1, we cannot
draw firm conclusions. Further investigations will
therefore be required to clarify whether genetic
variations in the genes investigated in this study are
associated with ADHD. The predominant reason for
the difficulty in identifying association risk alleles is
the very small effect sizes observed for even the most
replicated association findings with ADHD. This is
demonstrated by the data from DRD4 and DAT1,
where we can only conclude that a believable level of
evidence has been obtained due to the numerous
preceding studies and conclusions from meta-ana-
lyses of world data, involving several thousand
diagnosed cases. In the case of DAT1 a recent meta-
analysis found no overall net effect of the 10-repeat
allele in Caucasian populations despite a large
number of positive reports; evidence of heterogeneity
and haplotype associations in the region are however
consistent with the association (Li et al., 2006)
and more work is required to identify functional
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variants in the region.96 The small OR identified for
polymorphisms within these two genes are similar to
those observed for both nominally significant and
nonsignificant findings in this study, indicating the
need for future studies to focus on several large
collaborative data sets to detect, and subsequently
replicate key findings.
In this study we faced several difficulties. Although
we were able to screen many of the associated SNPs
from previous studies, in some cases SNPs were
predicted to have a low chance of genotyping
successes on the Illumina platform, and were there-
fore left out of the SNP array. This was the case for
SNPs in SNAP-25 (rs3787283; rs6039806 and
rs362987, TPH2 (rs1487275; rs4570625), NET1
(rs2242447) and CHRNA4 (rs6090384 and
rs2273506). For seven of these SNPs we were able to
perform indirect assays, using a proxy SNP in strong
LD (R2 > 0.8) with the reported SNP. We were able to
achieve this since we included analysis of our SNP
array on the CEPH Caucasian panel used in the
HapMap project; enabling us to link by LD relation-
ship many non-HapMap SNPs included in our study,
with SNPs on the HapMap database (in addition to
SNPs already on the HapMap database).
Another problem was that several published SNP
findings did not include ‘rs’ number nomenclature.
We were able to identify the majority of these SNPs
using PCR primer sequences, to ensure correct
identification of the relevant database SNP. There
were a few cases where we could not determine the rs
number or their precise location, and these may not
currently be on public databases. To ensure ease of
replication and minimise the potential for errors by
misidentification of SNPs, we recommend that future
investigators use the rs number nomenclature and
stick to database SNPs whenever possible. Novel
SNPs verified by individual studies, should be
submitted for inclusion into the public databases.
Inescapable from the genetic analysis of complex
genetic disorders in studies of this type are problems
of multiple testing. Rather than test everything we can
possibly test, we have made some considerations in
the name of keeping the number of tests limited. From
a single-marker standpoint, at a bare minimum, we
would only perform a single analysis for each SNP.
We expanded on that minimum, by utilising two
single marker analytic techniques, implemented in
UNPHASED and WHAP. These single marker ap-
proaches differ subtly but are largely correlated. That
correlation alleviates the multiple testing problem
that arises from the use of multiple techniques, as the
number of novel tests conducted under a secondary or
tertiary analysis are only as great as the amount of
signal independently assessed by that technique. As
we observe, a correlation of 0.70 between our P-values
for the single marker analysis in WHAP and UN-
PHASED, in effect, we have only carried out 1.3 times
as many tests with these two approaches, rather than
double. In our opinion, this is an acceptable burden
for the added information about the signal in the data
set, and confirmation that both methods are working
properly.
The second consideration for multiple testing is
how to treat the haplotype analysis. Haplotype
analysis differs from single marker analysis in that
the number of possible approaches is much greater
(e.g. sliding window analysis vs haplotype block vs
tSNPs; all haplotypes vs most significant; all haplo-
types vs some percentage cutoff). Additionally, the
interpretation of a haplotype association signal in the
absence of single marker association is by no means
clear. By conditioning on nominal significance as our
criteria for conducting haplotype analysis, we limited
our testing burden greatly. Obviously, we may have
missed some associations by not exhaustively looking
at our data, but we feel more confident about the
signals we do detect in our sample.
The third consideration is how to provide some
adjustment for the number of SNPs tested. We
approached this by empirically adjusting for the
number of tests across each gene. Although we could
have provided adjustment at the study wide level or
the genome wide level, none of the SNP or gene-wide
associations would have passed such stringent criter-
ia. Adjustment for the analysis of 51 genes in our
gene-wide significance tests would require a signifi-
cance level of 0.00099 after Bonferroni correction,
whereas our best gene-wide statistic was 0.012 for
PNMT. For risk alleles of very small effect, achieving
genome-wide significance levels may not be a
realistic target within the limitations of feasible
sample sizes, even where very large data sets are
collated through large multisite collaborations.
Whether such stringent test criteria are required
remains a controversial issue, with concerns about
‘throwing the baby out with the bathwater’ suggesting
that in the context of replication, necessary signifi-
cance thresholds may be dramatically lower than
genome-wide significance levels.36
In the future, association studies of ADHD will
draw on two main resources. First, the results of
linkage studies have already identified several re-
gions with a high chance of containing one or more
susceptibility loci for ADHD. The results of our
linkage scan during 2006 when combined with
linkage data from other sites will further delineate
the regions worth pursuing. Replication of several
loci in some of the existing linkage data (5p, 6q, 7p,
11q, 12q and 17p) is encouraging; since linkage is a
low powered method these data suggest that several
loci of more moderate effect size may exist. However,
the ability of association to detect such loci will
depend critically on the whether linkage signals are
the result of common risk variants or multiple rare
variants. Although this cannot be determined in
advance of high-density association studies, previous
data from other complex behavioural disorders
suggest that association findings within linkage
regions do not generally account for the entire linkage
signal, suggesting the existence of more than one risk
variant within linkage regions.
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The ability to perform high-density genome-wide
screens for common risk variants using contemporary
genome wide SNP arrays is expected to greatly speed
the process of novel gene identification for complex
disorders.58 However, the ability to detect meaningful
‘signals’ above the background ‘noise’ generated by
investigating hundreds of thousands of genetic mar-
kers is likely to present a major hindrance to progress.
Successful identification of novel gene associations
will need to utilise large initial studies to reliably
detect putative association, and large replication
samples. Statistical information will subsequently
need to be supplemented by functional analysis and
interpretation that seek to make biological sense of
association findings.36
Despite the availability of high-density SNP infor-
mation from public databases and use of the highly
efficient Illumina platform for customised SNP
analysis, we still found difficulties in selecting a
sufficiently representative sets of informative SNPs.
There were two main constraints. First, we found that
many SNPs within or close to ‘functional’ gene
regions did not appear on the HapMap database,
and could not therefore be knowingly detected by
selection of tSNPs. Out of 1105 SNPs selected for their
location within functional regions, only 381 (34.8%)
had been genotyped in the HapMap CEPH panel; so
no LD information was available for these markers at
the start of the investigation. We have now genotyped
all markers included in this study in the CEPH panel
and these data will be presented elsewhere. Many of
the ‘functional’ SNPs had no NCBI validation status
and within this group we found a very low rate of
polymorphism, around 84%. This rate is much lower
than the 30–50% estimated in the recent past. This
suggests that as the number of validated SNPs
increases, the proportion of residual (nonvalidated)
SNPs that are polymorphic is decreasing.
Another limiting factor was the estimated chance of
a successful assay on the Illumina platform. Although
in general sufficient SNPs could be selected for a
high-density screen of each gene, there were instances
when SNPs that we wished to select had a low chance
of successful genotyping. Across the genes that we
selected for investigation in this study, we identified
7902 potential database SNPs. Of these 982 (12.4%)
had a design rating of zero, meaning that it was not
possible to design a working genotype assay; and 381
(4.8%) had a design rating of 0.5, meaning an
approximate 50% chance of designing a working
assay. Analysis was also incomplete for X-linked
genes, due to the lack of information on polymorphic
markers in HapMap and nonimplementation of
chromosome X analyses in tagging programs such as
CLUSTAG and HAPLOVIEW.
A potential limitation of this study was site
heterogeneity since we collected ADHD probands
and their families from 12 sites across eight European
countries. There are however several factors that
minimise our concerns. Many of the European sites
involved in this study have more than a decade long
track record of collaborative research as members of
the European Network for Hyperactivity Disorders
(Eunethydis) consortium, which has yearly meetings
devoted to collaborative studies of ADHD, and many
of the issues related to collaborative clinical research,
such as agreement on diagnostic methods, have been
resolved. In this study, we have been able to adopt the
same diagnostic procedures across all sites, and
investigators performing clinical diagnostic proce-
dures have received a common training package. The
PACS interview used as the main diagnostic instru-
ment has the advantage for multisite studies that
cultural differences in perception of behavioural
thresholds for each symptoms item are minimised,
since investigators make objective ratings of observed
behaviours. The same algorithm is then applied to
these behavioural observations, establishing opera-
tional criteria for calling each symptom.
We have further sort to reduce aetiological hetero-
geneity by targeting DSM-IV combined subtype
ADHD and excluding individuals with possible
autism, providing a sample with considerable clinical
homogeneity. We chose to identify cases with a
combination of home and school based measures
(PACS for home and other situations and Conners for
classroom). This provides a refined phenotype of
children whose problems are pervasive across situa-
tions. Situation specific hyperactivity (children
whose hyperactivity presents only at home or only
at school) can be included in ADHD if only one
measure is used, but this goes against the spirit of
both ICD-10 and DSM-IV. It is not at all clear that
problems seen only at school, or only at home, have
the same biological basis. Indeed, some evidence from
twin studies indicates that to some extent there may
be different genetic influences on behaviour in the
two settings.59 Ho et al.60 surveyed a school popula-
tion with parent and teacher questionnaires, and
selected those who showed hyperactive behaviour at
home only, at school only, or pervasively across both
situations. The home specific group showed less
evidence of cognitive problems and more evidence of
family conflict and adversity, whereas the school
specific group showed more evidence of academic
learning difficulties. A study of subgroups in a
clinically referred population in the UK found that
the behaviour problems in the school-situational
group tended to appear later, only after school entry.54
It was only in the group identified both by parents
and by teachers that the typical neurodevelopmental
associations of ADHD emerged. This pervasive group
was identified in both the Ho et al.60 and Taylor
et al.59 studies, using the same measures (teacher
Conners and PACS) as in our investigation.
The potential for population heterogeneity was
minimised by restricting ascertainment to individuals
of white European origin, comparable to a multisite
collection of European-Americans. We also restricted
our analyses to allelic tests of transmission from
heterozygote parents (TDT), limiting the impact of
population differences in MAFs. Although use of the
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TDT provides excellent protection from population
stratification effects, there is some evidence that
analysis of case–control data may be associated with
stronger genetic effects. This may be due at least in
part to the increased severity of ADHD probands in
samples where collecting DNA from parents is not a
requirement for inclusion into a study.61 We will
include case–control investigations in some future
studies using this sample.
The possibility that risk alleles may differ in
prevalence is handled in our statistical procedures
that assume homogeneity. The power to detect
associations is therefore determined by the average
effect size in the combined sample. As discussed
above, it is reassuring that this large multisite study
provided estimates of OR for the known VNTR alleles
in DRD4 and DAT1 that were very close to those
estimated from a recent meta-analysis of multisite
data. Interpretation of these data is limited in one
way; if we detect an OR of 1.5, we do not know
whether this is a large effect in a subset of samples, or
a modest effect across the entire sample. Although
this can be formally tested, preliminary inspection
suggested no site heterogeneity for the SNP associa-
tions, and since heterogeneity analysis does not add
power for detection of gene associations, we have not
presented these data here. Our genotyping strategy
minimised the potential for site differences due to
systematic genotype error, by using the same DNA
extraction procedures, collecting all DNA at one site,
partial randomisation of samples across DNA plates,
and use of the high accuracy Illumina platform.
Concluding remarks
We have conducted a large multi site association study
of 674 DSM-IV ADHD probands to screen 925 SNPs in
52 candidate genes. Our findings are consistent with
the two most replicated findings in ADHD research,
with VNTR markers in DRD4 and DAT1. We identified
16 additional genes with one or more nominally
associated SNPs, including eight genes that passed
gene-wide tests that controlled for the number of SNPs
analysed in each gene. Since none of the findings were
significant if adjusted at the study wide or genome-
wide level, we are unable to identify any specific
genetic variant that are more likely to be true risk
factors for ADHD. Since overall we found more
significant SNPs that expected, further investigations
of these SNP markers are required in large replication
samples, to enable positive identification of risk alleles
from these findings. Future association studies of
ADHD are likely to need several samples of around
1000 probands or more to identify the most prominent
genetic risk factors for this important common dis-
order.
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